                </a></li></ul></div><p><strong>Figure 9.  <span>Therapeutic efficacy of rCE/CPT-11 NDEPT.</span></strong></p><a id="article1.body1.sec3.sec6.fig1.caption1.p1" name="article1.body1.sec3.sec6.fig1.caption1.p1"></a><p>Mice (10/group) received one of the following: 1) 2 million HB1.F3.C1 cells transduced with AdCMVrCE (MOI = 20) encoding a secreted form of rCE; 2) CPT-11 (7.5 mg/kg) alone; 3) transduced HB1.F3.C1 cells and CPT-11 (7.5 mg/kg).</p>
<a id="article1.body1.sec3.sec6.fig1.caption1.p2" name="article1.body1.sec3.sec6.fig1.caption1.p2"></a><p>Animals that received HB1.F3.C1/AdCMVrCE cells with CPT-11 survived significantly longer than mice receiving only HB1.F3.C1/AdCMVrCE cells (<em>P</em>&lt;0.0001) or only CPT-11 (<em>P</em>&lt;0.001), suggesting an enhanced tumor targeting and tumor cell-killing effect of CPT-11.</p>
